Corbus Pharmaceuticals CRBP has emerged as an unusual way for investors to gain exposure to the cannabis space. The company recently announced positive results from an early-stage study on its obesity candidate CRB-913, an oral cannabinoid (CBD)-based small molecule. CRB-913 Gives CRBP's Cannabis Bet a Boost CRB-913 is a second-generation cannabinoid type-1 (CB1) receptor inverse agonist drug being developed for obesity. On Monday, Corbus reported data from the phase Ib CANYON-1 study, which showed that treatment with once-daily CRB-913 achieved statistically significant and clinically meaningful weight loss across all three dose levels — 20 mg, 40 mg and 60 mg — at 12 weeks. The 20-mg and 40-mg doses delivered placebo-adjusted mean weight loss of 2.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。